- Primary research
- Open Access
Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
© Ding et al.; licensee BioMed Central Ltd. 2014
- Received: 19 September 2014
- Accepted: 22 November 2014
- Published: 5 December 2014
Burkitt’s lymphoma is an aggressive malignancy with high risk of metastasis to extranodal sites, such as bone marrow and central nervous system. The prognosis of metastatic Burkitt’s lymphoma is poor. Here we sought to identify a role of histone deacetylase 6 (HDAC6) in the metastasis of Burkitt’s lymphoma cells.
Burkitt’s lymphoma cells were pharmacologically treated with niltubacin, tubacin or sodium butyrate (NaB) or transfected with siRNAs to knock down the expression of HDAC6. Cell migration and invasion ability were measured by transwell assay, and cell cycle progression was analyzed by flow cytometry. Cell adhesion and proliferation was determined by CellTiter-Glo luminescent cell viability assay kit. Cell morphological alteration and microtubule stability were analyzed by immunofluorescence staining. Effect of niltubacin, tubacin and NaB on acetylated tubulin and siRNA efficacy were measured by western blotting.
Suppression of histone deacetylase 6 activity significantly compromised the migration and invasion of Burkitt’s lymphoma cells, without affecting cell proliferation and cell cycle progression. Mechanistic study revealed that HDAC6 modulated chemokine induced cell shape elongation and cell adhesion probably through its action on microtubule dynamics.
We identified a critical role of HDAC6 in the metastasis of Burkitt’s lymphoma cells, suggesting that pharmacological inhibition of HDAC6 could be a promising strategy for the management of metastatic Burkitt’s lymphoma.
- Burkitt’s lymphoma
- histone deacetylase 6
- Cell shape elongation
- Microtubule dynamics
Burkitt’s lymphoma (BL) as a highly aggressive B-cell malignancy, usually occurs in adolescent as well as in patients with immune defect. Endemic BL is the most common variant and prevails in Africa where almost all the patients are found with Epstein-Barr Virus (EBV) infection ,. Besides, there are two other BL variants: sporadic BL which accounts for about 30-50% of childhood lymphomas in the developed countries, and HIV infection caused immune-deficient associated type . BL grows rapidly, potentially doubling in size every day, which leads to its sensitivity to chemotherapeutic agents. Currently most of the childhood BL is effectively managed with the cyclical intensive chemotherapy . However, another feature of BL is its high aggression, occasionally disseminates to bone marrow (BM) and central nervous system (CNS), contributing to poor prognosis in clinics . Therefore, attempts to explore better regimens to inhibit the metastasis of BL is urgently needed.
Histone deacetylases (HDACs) are a superfamily comprising of 18 proteins, which regulate gene expression through deacetylation of histones to produce a highly compact chromatin structure ,. Besides, HDACs interact with many non-histone substrates to regulate diverse cellular activities, including cell division, cell motility, and angiogenesis ,, making targeting HDACs being a promising approach for treatment of various malignancy. Several HDAC inhibitors have demonstrated excellent inhibitory effects on tumor growth , for instance, panobinostat, a pan-HDAC inhibitor, hold great promise in several hematological malignancy including cutaneous T-cell lymphoma, Hodgkin lymphoma, and B-cell lymphoma in both preclinical study and clinical trials . However, due to the significance of HDACs in cellular activities, severe adverse effects, such as thrombocytopenia are also observed. Therefore, elucidating the role of each HDAC member in tumors could shed light to the development of better regimens against cancers. HDAC6 is a unique member of HDAC family, which is localized predominantly in the cytoplasm . Unlike the other HDAC members, HDAC6 bears two catalytic HDAC domains and has minimal effect on cell cycle related gene expression and cell proliferation , making its role in malignant tumors elusive. In this study, we adopted tubacin, niltubacin (deacetylase inactive tubacin derivatives), and sodium butyrate (NaB) to elucidate the role of HDAC6 in BL. Tubacin is a specific inhibitor of HDAC6, while NaB is a HDAC activity which lacks activity on HDAC6 . Our data demonstrated that inhibition of HDAC6 activity significantly suppressed SDF-1α induced cell shape elongation and cell adhesion, thereby leading to impaired cell motility without affecting cell proliferation.
BL is an aggressive B cell malignant disease with high risk of metastasis to extranodal sites. The prognosis for BL with involvement of BM and CNS is poor. Thus, attempts to explore agents to inhibit the metastasis of BL is greatly needed. In this study, we found that HDAC6 plays a crucial role in SDF-1α induced cell morphological changes. It is noteworthy that cell polarization towards elongated shape is prerequisite for cell migration and invasion ,. Further study confirmed that suppression of HDAC6 significantly restrained the motility of Raji cells. These findings thus suggest that targeting HDAC6 might be a potential strategy for management of metastatic BL.
HDAC inhibitors have been proved to be effective for several types of cancer, immune disorders, and neurodegenerative diseases -. Currently almost all the extensively studied HDAC inhibitors are non-selective, such as vorinostat, romidepsin, and panobinostat . In spite of excellent potency on shrinking tumors, these agents lead to inevitable adverse effects sometimes. Thus, elucidating the exact mediator responsible for the inhibitory effect on tumors is obligated. It is reported that HDAC2 suppresses the expression of p53, causing cell survival and insensitivity to chemotherapeutic agents ,. In addition, loss of HDAC5 restrains the cell proliferation of hepatocellular carcinoma by regulation of p21 and cyclin D1, thereby leading to cell cycle arrest and apoptosis . In this scenario, we revealed that HDAC6 did not affect the proliferation and cell cycle progression of Raji cells, which is consistent with the results found in mouse embryonic stem cells . Regarding little cytotoxicity of HDAC6 inhibitors in BL cells, it would be interesting in the future to investigate the efficiency of HDAC6 inhibitors combined with genotoxic agents or radiotherapy for the management of advanced BL.
It is believed that microtubule cytoskeleton is exquisitely modulated to fulfill their distinct function, such as mitosis, differentiation, directed cell movement, and vehicle transport -. HDAC6 is identified as a microtubule-binding protein, which regulates microtubule dynamics through deacetylation of α-tubulin . In addition, several other HDAC6 substrates have been identified, including cortactin, MAP7 domain-containing protein 3 (Mdp3), and heat shock protein 90 (HSP-90) -. As microtubule dynamics is essential for the establishment of cell polarity, turnover of focal adhesion, and cell motility, we concentrated on α-tubulin in this study. Our data revealed that microtubule stability against cold-induced depolymerizing condition was promoted in pharmacologically treated cells other than in HDAC6-depleted cells, which was consistent with the observation found in MCF-7 cells . Taken together, these findings demonstrate that HDAC6 modulates the acetylation level of α-tubulin, leading to chemokine induced microtubule remodeling and directed movement of BL cells, which provides the basis for pharmacological inhibition of HDAC6 as a potential approach for metastatic BL.
Tubacin (HDAC6 selective inhibitor) and NaB (a HDAC inhibitor without activity on HDAC6) were purchased from Santa Cruz Biotech (CA, USA). Niltubacin (deacetylase inactive tubacin derivatives) was purchased from Abcam (MA, USA). Antibodies against α-tubulin and acetylated tubulin were purchased from Abcam (MA, USA). SDF-1α, DAPI and propidium iodide (PI) were form Sigma (MO, USA), and CellTiter-Glo luminescent cell viability assay kit was from Promega (WI, USA). Fibronectin and Transwell were purchased from BD Biosciences (NJ, USA) and Corning (MA, USA), respectively. SiRNAs targeting luciferase (control) and HDAC6 were synthesized by Invitrogen (Beijing, China).
Cell culture and transfection
Human Burkitt’s lymphoma Raji and Namalwa cells were purchased from the American Type Culture Collection (ATCC), and maintained in the RPMI1640 medium supplemented with 10% FBS. SiRNAs were transfected into cells by using lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruction.
Cell proliferation assay
Cells were seeded at 6000 cells/well 12 hours prior to DMSO, NaB, or tubacin exposure. At the indicated time, cell viability was determined by CellTiter-Glo luminescent cell viability assay kit according to the manufacture’s protocol.
Cells were lyzed in cell lysis buffer containing 1% Triton X-100, 150 mM NaCl, and 50 mM Tris. Proteins were separated by 10% SDS-PAGE gel electrophoresis, and then transferred onto PVDF membranes. The membranes were blocked in Tris-buffered saline containing 5% fat-free dry milk and 0.2% Tween 20. After incubation with primary antibodies, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies. The proteins of interest were detected with enhanced chemiluminescence detection reagent according to the manufacturer’s instructions.
Cell cycle progression analysis
Raji cells treated with DMSO, NaB (1 μM), or tubacin (1 μM) were collected and washed twice with ice-cold phosphate-buffered saline (PBS). Then cells were fixed with 70% ethanol at 4°C for 24 hours. After twice wash with PBS, cells were incubated with propidium iodide (PI)/RNase A solution for 30 minutes. Samples were examined with a BD FACS Calibur Flow Cytometer.
Cell motility assays
Cell motility assays were carried out as described  with minor modification. For cell migration assay, Raji cells or Namalwa cells suspended in serum free medium were plated into inserts, and for cell invasion assay, cells suspended in serum free medium were plated into inserts which were precoated with Fibronectin (50 ng/ml) for overnight. DMSO, NaB (1 μM), or tubacin (1 μM) was added to the inserts, and then the inserts were placed in a 24-well plate containing the serum free medium supplemented with SDF-1α (100 ng/ml). 12 hours later, cells in the lower chambers were analyzed by a BD FACS Calibur Flow Cytometer.
Cell adhesion assay
Prior to SDF-1α (100 ng/ml) stimulation, Raji cells were treated with DMSO, NaB (1 μM), or tubacin (1 μM) for 3 hours. Then cells were plated into a 96-well plate which were precoated with Fibronectin (50 ng/ml) to allow cell adherence for 30 minutes. Subsequently cells were washed with PBS three times to remove the non-adherent cells, and adherent cells were measured by CellTiter-Glo luminescent cell viability assay kit.
Immunofluorescence staining was performed as described . In brief, cells grown on glass coverslips were fixed with 4% paraformaldehyde for 30 minutes. Cells were washed for three times with PBS, followed by incubation with 2% bovine serum albumin for 20 minutes. Then cells were sequentially incubated with primary antibodies and fluorescein-conjugated secondary antibodies. The nuclei were counterstained with DAPI. Coverslips were mounted with 90% glycerol in PBS and imaged with a Zeiss fluorescence microscope.
Microtubule stability analysis
Raji cells were incubated with DMSO, NaB, niltubacin or tubacin or transfected with HDAC6 siRNA for 24 hours, then cells were incubated on ice for 0 or 20 minutes. Cells were then fixed and immunostained with antibodies against α-tubulin and acetylated tubulin.
All data were derived from three independent experiments, and expressed as means ± SD. Student’s t-test and one-way analysis of variance (ANOVA) were performed for statistical analysis. P value < 0.05 indicates statistical significance.
This work was financially supported by NSFC (No. 81201873 and 81470368), Beijing Natural Science Foundation (No. 7132050) and 973 program (2011CB504303).
- Manne RK, Madu CS, Talla HV: Maxillary sporadic Burkitt's lymphoma associated with neuro-orbital involvement in an Indian male. Contemp Clin Dent. 2014, 5 (2): 231-235. 10.4103/0976-237X.132357.View ArticlePubMed CentralPubMedGoogle Scholar
- Mbulaiteye SM: Burkitt Lymphoma: beyond discoveries. Infect Agent Cancer. 2013, 8 (1): 35-10.1186/1750-9378-8-35.View ArticlePubMed CentralPubMedGoogle Scholar
- Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI: Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012, 490 (7418): 116-120. 10.1038/nature11378.View ArticlePubMed CentralPubMedGoogle Scholar
- Afanas N, Carvalho M, Almeida M, Costa V, Silva I, Oliva T: Burkitt's lymphoma. Acta Med Port. 2011, 24 (5): 735-738.PubMedGoogle Scholar
- Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gerard L, Oksenhendler E: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood. 2007, 110 (8): 2846-2854. 10.1182/blood-2006-10-051771.View ArticlePubMedGoogle Scholar
- Hess-Stumpp H: Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol. 2005, 84 (2–3): 109-121. 10.1016/j.ejcb.2004.12.010.View ArticlePubMedGoogle Scholar
- Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: What are the cancer relevant targets?. Cancer Lett. 2009, 277 (1): 8-21. 10.1016/j.canlet.2008.08.016.View ArticlePubMedGoogle Scholar
- Li D, Xie S, Ren Y, Huo L, Gao J, Cui D, Liu M, Zhou J: Microtubule-associated deacetylase HDAC6 promotes angiogenesis by regulating cell migration in an EB1-dependent manner. Protein Cell. 2011, 2 (2): 150-160. 10.1007/s13238-011-1015-4.View ArticlePubMedGoogle Scholar
- Lafarga V, Aymerich I, Tapia O, Mayor F, Penela P: A novel GRK2/HDAC6 interaction modulates cell spreading and motility. EMBO J. 2012, 31 (4): 856-869. 10.1038/emboj.2011.466.View ArticlePubMed CentralPubMedGoogle Scholar
- Slingerland M, Guchelaar HJ, Gelderblom H: Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anticancer Drugs. 2014, 25 (2): 140-149. 10.1097/CAD.0000000000000040.View ArticlePubMedGoogle Scholar
- Khot A, Dickinson M, Prince HM: Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs. 2013, 22 (9): 1211-1223. 10.1517/13543784.2013.815165.View ArticlePubMedGoogle Scholar
- Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP: HDAC6 is a microtubule-associated deacetylase. Nature. 2002, 417 (6887): 455-458. 10.1038/417455a.View ArticlePubMedGoogle Scholar
- Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A. 2003, 100 (8): 4389-4394. 10.1073/pnas.0430973100.View ArticlePubMed CentralPubMedGoogle Scholar
- Laird DJ, Altshuler-Keylin S, Kissner MD, Zhou X, Anderson KV: Ror2 enhances polarity and directional migration of primordial germ cells. PLoS Genet. 2011, 7 (12): e1002428-10.1371/journal.pgen.1002428.View ArticlePubMed CentralPubMedGoogle Scholar
- Wojciak-Stothard B, Ridley AJ: Shear stress-induced endothelial cell polarization is mediated by Rho and Rac but not Cdc42 or PI 3-kinases. J Cell Biol. 2003, 161 (2): 429-439. 10.1083/jcb.200210135.View ArticlePubMed CentralPubMedGoogle Scholar
- Lawless MW, Norris S, O'Byrne KJ, Gray SG: Targeting histone deacetylases for the treatment of disease. J Cell Mol Med. 2009, 13 (5): 826-852. 10.1111/j.1582-4934.2008.00571.x.View ArticlePubMed CentralPubMedGoogle Scholar
- Falkenberg KJ, Johnstone RW: Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014, 13 (9): 673-691. 10.1038/nrd4360.View ArticlePubMedGoogle Scholar
- Pandey UB, Batlevi Y, Baehrecke EH, Taylor JP: HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy. 2007, 3 (6): 643-645. 10.4161/auto.5050.View ArticlePubMedGoogle Scholar
- Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, London WB, Marshall GM, Lock RB, Liu T: Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget. 2014, 5 (12): 4257-4268.View ArticlePubMed CentralPubMedGoogle Scholar
- Wagner T, Brand P, Heinzel T, Kramer OH: Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis. Biochim Biophys Acta. 2014, 1846 (2): 524-538.PubMedGoogle Scholar
- Fan J, Lou B, Chen W, Zhang J, Lin S, Lv FF, Chen Y: Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumour Biol. 2014, 35 (11): 11523-11532. 10.1007/s13277-014-2358-2.View ArticlePubMedGoogle Scholar
- Tala Xie S, Sun X, Ran J, Zhang L, Li D, Liu M, Bao G, Zhou J: Microtubule-associated protein mdp3 promotes breast cancer growth and metastasis. Theranostics. 2014, 4 (10): 1052-1061. 10.7150/thno.9727.View ArticleGoogle Scholar
- Brugues J, Nuzzo V, Mazur E, Needleman DJ: Nucleation and transport organize microtubules in metaphase spindles. Cell. 2012, 149 (3): 554-564. 10.1016/j.cell.2012.03.027.View ArticlePubMedGoogle Scholar
- Ben-Ze'ev A: The role of changes in cell shape and contacts in the regulation of cytoskeleton expression during differentiation. J Cell Sci Suppl. 1987, 8: 293-312. 10.1242/jcs.1987.Supplement_8.16.View ArticlePubMedGoogle Scholar
- Tala Sun X, Chen J, Zhang L, Liu N, Zhou J, Li D, Liu M: Microtubule stabilization by Mdp3 is partially attributed to its modulation of HDAC6 in addition to its association with tubulin and microtubules. PLoS One. 2014, 9 (3): e90932-10.1371/journal.pone.0090932.View ArticleGoogle Scholar
- Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, Yao TP, Lane WS, Seto E: HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 2007, 27 (2): 197-213. 10.1016/j.molcel.2007.05.033.View ArticlePubMed CentralPubMedGoogle Scholar
- Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005, 18 (5): 601-607. 10.1016/j.molcel.2005.04.021.View ArticlePubMedGoogle Scholar
- Asthana J, Kapoor S, Mohan R, Panda D: Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells. J Biol Chem. 2013, 288 (31): 22516-22526. 10.1074/jbc.M113.489328.View ArticlePubMed CentralPubMedGoogle Scholar
- Xie S, Chen M, Yan B, He X, Chen X, Li D: Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. PLoS One. 2014, 9 (4): e94496-10.1371/journal.pone.0094496.View ArticlePubMed CentralPubMedGoogle Scholar
- Xie S, Dong B, Sun X, Tala He X, Zhou J, Liu M, Li D: Identification of a cytoplasmic linker protein as a potential target for neovascularization. Atherosclerosis. 2014, 233 (2): 403-409. 10.1016/j.atherosclerosis.2014.01.009.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.